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Abstract Despite the apparent appropriateness of left
ventricular (LV) remodeling following myocardial infarc-
tion (MI), it poses an independent risk factor for develop-
ment of heart failure. There is a paucity of studies into the
molecular mechanisms of LV remodeling in large animal
species. We took an unbiased molecular approach to
identify candidate transcription factors (TFs) mediating the
genetic reprogramming involved in post-MI LV remodel-
ing in swine. Left ventricular tissue was collected from
remote, non-infarcted myocardium, 3 weeks after MI-
induction or sham-surgery. Microarray analysis identiﬁed
285 upregulated and 278 downregulated genes
(FDR\0.05). Of these differentially expressed genes, the
promoter regions of the human homologs were searched for
common TF binding sites (TFBS). Eighteen TFBS were
overrepresented [two-fold (p\0.01) in upregulated and
13 in downregulated genes. Left ventricular nuclear protein
extracts were assayed for DNA-binding activity by protein/
DNA array. Out of 345 DNA probes, 30 showed signal
intensity changes [two-fold. Five TFs were identiﬁed in
both TFBS and protein/DNA array analyses, which showed
matching changes for COUP-TFII and glucocorticoid
receptor (GR) only. Treatment of swine with the GR
antagonist mifepristone after MI reduced the post-MI
increase in LV mass, but LV dilation remained unaffected.
Thus, using an unbiased approach to study post-MI LV
remodeling in a physiologically relevant large animal
model, we identiﬁed COUP-TFII and GR as potential key
mediators of post-MI remodeling.
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Introduction
Heart failure is currently the only major cardiovascular
syndromeofwhichtheprevalenceissteadilyincreasing.For
a signiﬁcant part this is the result of improved survival of
patientsencounteringanacutemyocardialinfarction(MI)in
conjunction with an ageing population [59]. Loss of viable
myocardiumelicitsacascadeofcompensatorymechanisms,
including neurohumoral activation, ﬂuid retention and left
ventricular (LV) remodeling, in an attempt to maintain
normal pump function [27, 54]. However, despite its
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ofLVhypertrophyanddilation—constitutesanindependent
risk factor for the development of heart failure [63]. Mech-
anismsthathavebeenimplicatedinthepathologyofpost-MI
remodeling and heart failure include myoﬁlament dysfunc-
tion [48, 57], alterations in excitation–contraction coupling
[23] and mitochondrial function [25], decreased expression
of atrophy mediators [5], inﬂammatory responses [3,14, 31]
and alterations in extracellular matrix [19, 47] and cell–cell
interactions [32].
The molecular pathways underlying LV remodeling and
its progression toward heart failure remain incompletely
understood. The majority of studies into the molecular
mechanisms of LV remodeling has been reductionistic in
nature and has principally been performed in mice. These
studies have yielded a wealth of information regarding the
role of individual genes and proteins in LV remodeling
[38]. However, there are marked differences in cardiac
physiology between rodents and large mammals [10, 21].
Nevertheless, there is a paucity of studies into the molec-
ular mechanisms of cardiac remodeling in large animal
species mainly because the use of large animal models in
molecular ‘–omics’ studies was limited by a lack of suit-
able tools together with incomplete annotation of the
genome, transcriptome and proteome. However, porcine
gene-expression arrays in conjunction with improved
annotation have recently become available [6], allowing
analysis of the molecular alterations in LV remodeling in
pigs.
To identify candidate transcription factors (TFs) that
mediate the genetic reprogramming involved in LV
remodeling in the pig, we took an unbiased molecular
approach (Fig. 1). First, global changes in gene expression
were studied by microarray analysis of the remote non-
infarcted LV tissue early after induction of MI. To identify
the responsible transcription factors, these data were sub-
sequently combined with transcription factor binding site
(TFBS) analysis as well as with protein–DNA arrays using
LV nuclear protein extracts. Rationale for this approach
was that the coordinate upregulation and downregulation of
a high number of different genes is likely achieved through
altered function of a limited set of TFs. This integrated
approach led to the identiﬁcation of COUP-TFII and the
glucocorticoid receptor as potential mediators of post-MI
LV remodeling.
Methods
Experimental animals
Animal experiments were performed in accordance with
the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, revised 1996) and with
approval of the Erasmus Medical Center Animal Care
Committee. 51 pre-adolescent (2–3 months old) York-
shire 9 Landrace swine (22.0 ± 0.4 kg) of either sex were
used; males had been neutered.
Surgery
The animals were sedated with ketamine (20 mg/kg,
intramuscularly (IM)) and midazolam (0.5 mg/kg, IM),
anesthetized with thiopental (10 mg/kg, intravenously
(IV)), intubated and ventilated with O2/N2 (1/2 v/v) enri-
ched with 0.1–1% (vol/vol) isoﬂurane [51, 57]. Following a
thoracotomy through the fourth left intercostal space, the
heart was exposed via a small pericardial incision, the left
circumﬂex artery (LCx) was dissected and a suture was
placed around it. Subsequently, the LCx was permanently
ligated in 31 swine designated to the MI group (producing
a transmural infarction in the lateral wall encompassing
20–25% of the left ventricle [58]), while the suture was
Fig. 1 Workﬂow of our transcriptional genomics approach. RNA and
nuclear proteins were isolated from LV tissue. The RNA was used in
microarray analysis followed by TFBS analysis of differentially
expressed genes. Nuclear protein extracts were used for protein/DNA
array analysis to identify TFs that were increased or decreased in
DNA-binding activity in post-MI hearts. Candidate TFs were
identiﬁed by combining these two data sets. LV left ventricular, MI
myocardial infarction, TFBS transcription factor binding site, DE
differentially expressed, TF transcription factor
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57, 58]. Then the pericardium and the chest were closed
and animals were allowed to recover, receiving analgesia
(0.3 mg buprenorphine IM) for 2 days and antibiotic pro-
phylaxis (25 mg/kg amoxicillin and 5 mg/kg gentamycin
IV) for 5 days.
Echocardiography and hemodynamic measurements
Three weeks after surgery, the animals were sedated with
ketamine (20 mg/kg, IM) and midazolam (0.5 mg/kg, IM)
and underwent echocardiography for the determination of
LV end-diastolic cross-sectional area (EDA) and end-sys-
tolic cross-sectional area (ESA) [11]. 2D ejection fraction
was calculated as 100 9 (EDA - ESA)/EDA %. After
induction of anesthesia with pentobarbital (10–15 mg/kg
per h, IV) swine were instrumented for measurement of
mean arterial pressure, heart rate, cardiac output, rate of
rise in LV pressure at 40 mm Hg (LV dP/dtP40), time
constant of relaxation (tau) and LV end diastolic pressure
[11, 57, 58]. After completion of all measurements, the
animals underwent a sternotomy and the heart was arrested
and immediately excised. The left ventricle was divided
into subendocardial and subepicardial tissue from the
anterior, lateral, posterior and septal area of the LV wall
and cardiac tissue was snap-frozen in liquid nitrogen (i.e.,
within 3–5 min of excising the heart) and stored at -80C.
For protein and RNA analysis, subendocardial tissue from
the anterior wall was used, which is the remote non-
infarcted area in MI animals.
Total RNA isolation
RNA was extracted from LV tissue from eight MI and
eight sham animals (four males and four females per
group). The frozen tissue samples were pulverized with a
mortar and pestle and TRI reagent (Invitrogen, Carlsbad,
CA, USA) was added immediately to the powder. The
RNA was isolated according to manufacturer’s instruc-
tions, and cleaned with RNeasy clean-up kit (Qiagen,
Valencia, CA, USA). Purity and quality of isolated RNA
were assessed by RNA 6000 Nano assay on a 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA, USA).
All samples showed a RNA integrity number[8.
Microarray analysis
Sixteen microarrays, eight for sham and eight for post-MI
hearts, were run in three independent batches. From each
heart, RNA (3 lg) was used for synthesis of biotinylated
cRNA. Labeled cRNA was hybridized to the GeneChip
Porcine Genome Array (Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s instructions. The
Affymetrix QC reports showed high quality of the samples
and arrays, indicated by percentage of present calls, noise,
background, and by a 30:50signal ratio for glyceraldehyde-
3-phosphate dehydrogenase mRNA of\1.4.
Raw intensity values of all samples were normalized in
R (http://www.r-project.org). The data were corrected for
variability across batches and arrays by quantile normali-
zation according to experimental group, followed by robust
microarray average normalization, using the Affy package
developed by Bioconductor [15]. The normalized expres-
sion values were loaded into Partek genomic suite (Partek
Inc, St. Louis, MO, USA) and multivariate principal
component analysis was performed [45]. All the micro-
array data have been submitted to the National Center for
Biotechnology Information (NCBI) Gene Expression
Omnibus database (GEO) (http://www.ncbi.nlm.nih.gov/
geo) with GEO accession number GSE27962.
The class comparison tool of BRB-ArrayTools software
(http://linus.nci.nih.gov/BRB-ArrayTools.html) was used
for generation of lists of differentially expressed genes
[49]. Genes were considered signiﬁcantly different
between MI and sham at a false discovery rate (FDR)
\0.05. As the annotation of the porcine genechip is far
from complete, the annotation of ANEXdb [6] was used.
This open source application aligns Affymetrix porcine
GeneChip target sequences to the Iowa Porcine Assembly,
which is an assembly of all publicly available porcine-
expressed consensus sequences. This was subsequently
aligned to the NCBI RefSeq RNA database, to yield the
homologous human RefSeq IDs.
Transcription factor binding site analysis
The genomic sequences of the human homologs of the
differentially expressed genes were selected, and regions
between position 500 upstream and 100 downstream of the
transcription start site were searched for putative tran-
scription factor binding sites (TFBS) using F-match
implemented in the Explain Analysis System (Biobase
GmbH, Wolfenbu ¨ttel, Germany) [29, 30]. The rationale for
searching differentially expressed genes for common TFBS
is the assumption that co-expressed genes are coordinately
regulated by a limited set of TFs. Promoter regions of the
differentially expressed genes were scanned for so-called
positional weight matrices [29], constructed from collec-
tions of known binding sites for a given TF. The TFBS
were searched using the entire vertebrate non-redundant set
of transcription factors matrix from the TRANSFAC
database [64]. To reduce false positive results in TFBS
analysis, the choice of an appropriate control data set is of
paramount importance. To identify TFBS that cause the
increased expression of the upregulated genes, the pro-
moters of the upregulated genes were taken as input set,
Basic Res Cardiol (2011) 106:1269–1281 1271
123while the promoters of the downregulated genes were taken
as background set. For the identiﬁcation of overrepresented
TFBSs in downregulated genes, the promoters of down-
regulated were used as input set and the promoters of
upregulated genes as background set. The number of
binding sites in the promoter region of upregulated and
downregulated genes per 600 basepairs for each TF is
indicated. Overrepresentation was determined using a one-
tailed Fisher exact probability test and considered signiﬁ-
cant when more than two-fold and at p\0.01.
Protein/DNA array
With the protein/DNA array (Combo array, Panomics/Af-
fymetrix, Milan, Italy), nuclear protein extracts were semi-
quantitatively assayed by DNA binding activity for 345
TFs. Nuclear protein extracts were prepared from LV tissue
as previously described [33]. Protein/DNA array analysis
was performed according to the manufacturer’s instruc-
tions. Brieﬂy, 5 lg of nuclear protein of a pool of four MI
extracts and a pool of four sham extracts was used for
binding to a mix of biotin-labeled TF-speciﬁc DNA probes
in solution. Subsequently, all unbound DNA probes were
washed away. The TF-bound probes were denatured and
then hybridized to the array membrane. After addition of
steptavidin–HRP, signals were generated by enhanced
chemiluminescence (ECL) and exposure to Hyperﬁlm ECL
(Amersham Biosciences, Piscataway, NJ, USA). Various
exposure times were used to obtain signals over a large
dynamic range. Signal intensities were quantiﬁed using a
Bio-Rad calibrated GS-800 scanner and Quantity One
software (Bio-Rad, Hercules, CA, USA). Only non-satu-
rated signals were used for further analysis. TF binding
activity was considered signiﬁcant when at least a two-fold
signal difference between MI and sham was present.
Ingenuity pathway analysis
Pathway analysis (Ingenuity Systems, Redwood City, CA,
USA) was performed to detect the biological functions and
molecular networks of the differentially expressed genes,
usingthehumanRefseqIDsasinput.Biologicalgroupswere
identiﬁed with which the genes are signiﬁcantly associated
(p\0.001).Interconnectivityofthegeneswasvisualizedby
the molecular networks constructed by the program. These
networks are constructed by connecting as many genes as
possible, also using unchanged hub molecules. For linking
TFs from the protein/DNA array to genes identiﬁed in the
microarray analysis, the TFs were used as input for pathway
analysis. In the build function and with the grow tool, the
genes were linked to the TFs if they are known from the
literature to be either expressed/transcribed by, or have an
experimentally validated binding site for the TFs.
Statistics
Data are presented as mean ± SEM. Differences between
two groups were analyzed by unpaired Student’s t-test.
Differences between three groups were analyzed by one-
way ANOVA followed by Student Newman-Keuls post-
hoc test using GraphPad Prism version 5.01 (GraphPad
Software, San Diego, CA, USA) and p\0.05 (two tailed)
was considered to be statistically signiﬁcant.
Results
LV remodeling and dysfunction after MI
Three weeks after MI-induction or sham surgery, LV
eccentric hypertrophy was evident from a 15% higher LV
to body weight ratio and a 70% larger LV end-diastolic
lumen area in MI animals (Table 1). LV remodeling was
associated with a maintained stroke volume and cardiac
output, but the 2D-ejection fraction was lower in MI
(37 ± 3%) than in sham (67 ± 3%) swine (p\0.05) due
to the increase in LV end-diastolic lumen area. Left ven-
tricular systolic dysfunction was also reﬂected in the 20%
lower LV dP/dtP40, while perturbed LV relaxation was
suggested by the 20% higher time constant of relaxation
Table 1 Anatomic, echocardiographic and hemodynamic data
Sham MI
Anatomic data (n = 20) (n = 24)
Body weight (kg) 30 ± 13 2 ± 1
RVW/BW (g/kg) 0.99 ± 0.05 1.35 ± 0.06***
LVW/BW (g/kg) 2.87 ± 0.09 3.38 ± 0.06***
Echocardiographic data (n = 9) (n = 13)
LV EDA (mm
2) 921 ± 47 1,551 ± 157**
LV ESA (mm
2) 306 ± 34 985 ± 128***
2D-ejection fraction (%) 67 ± 33 7 ± 3***
Hemodynamic data (n = 18) (n = 20)
MAP (mm Hg) 93 ± 59 4 ± 4
Heart rate (bpm) 115 ± 4 116 ± 7
Cardiac output (l/min) 3.4 ± 0.2 3.3 ± 0.2
Stroke volume (ml) 30 ± 23 0 ± 2
LV dP/dtP40 (mm Hg/s) 1743 ± 88 1,411 ± 51**
Tau (ms) 36 ± 24 3 ± 2*
LV EDP (mm Hg) 7.7 ± 0.8 13.0 ± 1.4**
Values are mean ± SEM
BW body weight, RVW and LVW, right and left ventricle weight, EDA
and ESA end-diastolic and end-systolic cross-sectional area, MAP
mean aortic pressure, LV dP/dtP40 rate of rise in LV pressure at
40 mm Hg, EDP end-diastolic pressure
* p\0.05; ** p\0.01; *** p\0.001 versus sham
1272 Basic Res Cardiol (2011) 106:1269–1281
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conjunction with right ventricular hypertrophy suggest the
presence of LV backward failure.
Gene expression analysis
Global differences in gene expression in the remote non-
infarcted part of the LV were determined by microarray
analysis. In principal component analysis 33.7% of the
variation in the data sets was explained by the ﬁrst two
components, with principal component 1 clearly separating
MI from sham animals (Fig. 2a). There was no apparent
clustering based on gender, which may be explained by the
use of pre-adolescent pigs and neutered males. In MI
swine, 285 genes were upregulated and 278 were
downregulated (FDR\0.05) compared to myocardium
from sham swine.
To test whether differentially expressed genes clustered
into ‘biological process’ groups, Ingenuity pathway ana-
lysis was used (Fig 2b). Besides ‘cardiovascular system
development and function’, genes involved in ‘cell-medi-
ated immune response’ and ‘inﬂammatory disease genes’
were signiﬁcantly overrepresented among differentially
expressed genes. These ﬁndings are in accordance with the
concept that inﬂammation plays an important role in post-
MI LV remodeling [40]. In addition, ‘lipid metabolism’
was signiﬁcantly overrepresented, which may reﬂect the
changes in energy metabolism associated with LV hyper-
trophy [66]. The genes that attribute to the subgroup
clustering in Fig. 2b are listed in supplemental Table 1.
Fig. 2 Differential gene expression. a Principal component analysis
of the data from the individual microarrays shows separation into two
groups, with the sham (blue) and post-MI (red) samples forming
separate clusters. Females (diamonds) and males (circles) do not form
separate clusters. b Clustering of the differentially expressed genes
into biological groups was performed with Ingenuity pathway
analysis (p\0.001). c, d The top two networks of differentially
expressed genes. Rectangles in green and red represent genes
downregulated and upregulated after MI compared with sham.
Dual-colored rectangles depict a group of genes, some of which
are upregulated and some are downregulated after MI. White
rectangles are hub molecules, of which the expression is not altered,
but that generally have a large number of connections with the genes.
Uninterrupted and dashed lines indicate physical and indirect
interactions between molecules, respectively
Basic Res Cardiol (2011) 106:1269–1281 1273
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relationships between the differentially expressed genes.
Figure 2c displays the network with the highest number of
genes. In this network NF-jB is a central hub molecule
whose expression is not changed at the mRNA level, but
which is known to be activated after MI in murine models
[28] and in the failing human heart [65]. Calcineurin is a
central hub molecule in the network with the second
highest number of differentially expressed genes (Fig. 2d),
and its role in cardiac hypertrophy in murine models has
been well established [36]. In this network the ‘Calmod-
ulin–A kinase anchor protein 5 (AKAP5)–protein kinase
A regulatory subunit 2B (PRKAR2B)–axis’ is present,
which was upregulated after MI. The latter observations
are consistent with previous data from our laboratory,
showing perturbations in PKA signaling in post-MI hearts
[57].
Transcription factor binding site analysis
To identify which TFs are involved in the coordinate
regulation of expression of differentially expressed genes,
we scanned promoter regions of the homologous human
genes for overrepresentation of transcription factor bind-
ing sites (TFBS). Eighteen TFBS were signiﬁcantly
overrepresented in promoter regions of the upregulated
genes, while 13 were overrepresented in the downregu-
lated genes (Table 2). These included a number of TFs
involved in cell differentiation and proliferation (e.g.,
serum response factor (SRF) and BTB and CNC homo-
logy 1 (BACH1)), and a number of nuclear receptors
(e.g., aryl hydrocarbon receptor (AhR), glucocorticoid
receptor (GR), chicken ovalbumin upstream promoter
transcription factor II COUP-TFII). For members of the
FOX family of TFs, a different binding site was over-
represented in the promoters of upregulated and down-
regulated genes. Transcription factor binding sites for the
nuclear factor of activated T-cells (NFAT) family of TFs
were overrepresented in the downregulated genes. For
each TFBS, the site was found on average in the proximal
promoter region of 10–30% of the differentially expressed
genes, whereas 37% of upregulated genes contained a site
for COUP-TFII (Table 2).
Protein/DNA array
To identify TFs with altered activity in remodeled myo-
cardium, we performed protein/DNA array analysis of
pooled LV nuclear extracts from eight post-MI hearts
versus eight sham swine. Signals above background were
detected for 186 out of the 345 probes in the array. DNA-
binding activity of 10 TFs was found to be at least two-fold
higher, while binding activity of 20 TFs was at least two-
fold less, in remodeled myocardium of post-MI hearts
compared to sham. Table 3 shows the top ﬁve of affected
TFs (see Supplemental Table 2 for the full list). Two TFs
were active only in one protein pool (Ikaros family zinc
ﬁnger 1 (IKZF1) in MI and retinoic acid receptor (RAR) in
sham), but signal intensity just surpassed the detection limit
of the array.
Ingenuity pathway analysis was performed to link the
TFs identiﬁed from the protein/DNA array to the differ-
entially expressed genes from the microarray analysis
(Fig. 3). The two TFs with the highest number of con-
nections to the genes were CCAAT/enhancer-binding
protein alpha (C/EBPa) and GR (also known as NR3C1).
Most of the identiﬁed TFs had few or no links to the dif-
ferentially expressed genes.
Five TFs were identiﬁed in both the in silico TFBS
analysis and the protein/DNA array. Paired box protein 8
(PAX8) and IKZF1 were overrepresented in the down-
regulated genes after MI, while their DNA-binding activity
was increased in remodeled myocardium, which could be
explained if these TFs were repressors of gene expression.
However, PAX8 is considered an activator of expression
[41] and IKZF1 can act both as activator and repressor
[16]. The transcriptional activator myogenic differentiation
(MyoD) [55] showed decreased DNA-binding activity,
while a TFBS, to which MyoD could bind was overrep-
resented in upregulated genes. For two TFs corresponding
data were found in TFBS and protein/DNA array analysis,
i.e. COUP-TFII (also known as NR2F2) and GR. As con-
nections with the microarray data set were more abundant
for GR than for COUP-TFII and since a pharmacological
antagonist of COUP-TFII is, to our knowledge, not cur-
rently available we selected GR for validation of our
transcriptional genomics approach.
Pharmacological blockade of GR
To test if GR is a critical mediator of LV remodeling, the
GR antagonist mifepristone [2] (Mifegyne, Nordic
Pharma BV, Baarn, the Netherlands) was administered to
a subset of seven MI pigs starting 1 day after the MI. The
animals received a daily dose of 200 mg p.o. for the ﬁrst
3 days of treatment, and 100 mg/kg p.o. thereafter until
the day of sacriﬁce. Mifepristone attenuated LV hyper-
trophy by 65% as reﬂected in the lower LVW/BW ratio
measured at 3 weeks after MI (Fig. 4). However, mife-
pristone treatment of MI pigs had no effect on LV end-
diastolic dimensions and did not improve 2D-ejection
fraction or LVdP/dtP40 compared to untreated MI pigs
(Fig. 4). In addition, mifepristone had no signiﬁcant effect
on stroke volume, cardiac output, tau, LV end-diastolic
pressure, or right ventricular hypertrophy (see Supple-
mental Table 3).
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The present study is the ﬁrst integrative unbiased investi-
gation into the transcriptional control of post-MI LV
hypertrophic remodeling in a large animal model, com-
bining microarray data with TFBS data-mining and nuclear
protein/DNA array data. Our approach identiﬁed two
potential key players in LV remodeling, i.e., COUP-TFII
and GR. Subsequent GR blockade revealed a critical role
of this nuclear receptor in post-MI LV hypertrophy in
swine, although it failed to blunt post-MI LV dilation.
In silico scanning of microarray data for TFBS in pro-
moter regions of genes, identiﬁed a number of TFBS that
were signiﬁcantly overrepresented in either upregulated or
downregulated genes. A number of these TFs have already
been implicated in murine models of cardiac hypertrophy.
SRF is part of the fetal gene program initiated after
hypertrophy, and its transcriptional activity is higher in
neonatal cardiomyocytes treated with hypertrophic stimuli
[7]. Furthermore, SRF overexpression in a transgenic
mouse model caused hypertrophy and cardiomyopathy
[67]. BACH1 has been implicated in cardiac hypertrophy
as knock-out mice display less hypertrophy following
pressure-overload [35]. In our analysis BACH1 was over-
represented in downregulated genes, which is in line with
its function as a transcriptional repressor [9]. Finally, AhR
is considered to be a negative regulator of cardiac hyper-
trophy, as AhR
-/- mice develop signiﬁcant cardiac
Table 2 Transcription factor binding sites overrepresented in upregulated or downregulated genes
Matrix name Transcription factor Up/down Frequency (sites/600 bp) p value
Up genes Down genes
V$HOXA3_01 HOXA3/4 5.6 0.11 0.02 0.001
V$SPIB_01 SPIB 4.7 0.12 0.03 0.001
V$PAX4_01 PAX4 4.4 0.11 0.03 0.002
V$PAX3_B PAX3 4.2 0.11 0.03 0.003
V$SRF_Q5 SRF 4.1 0.12 0.03 0.003
V$GR_Q6 GR (NR3C1) 3.2 0.13 0.04 0.006
V$TBX5_02 TBX5 3.1 0.16 0.05 0.002
V$SMAD_Q6 SMAD1-8 2.8 0.18 0.06 0.002
V$HNF4_01 HNF4gamma,HNF-4,HNF-4a 2.8 0.12 0.04 0.01
V$FOXD3_01 FOXC1/D1/D3/F1/F2/H1/I1/J1/J2FOXL1/O1/O3/O4 2.8 0.19 0.07 0.002
V$AR_03 AR 2.7 0.13 0.05 0.009
V$MYC_Q2 c-Myc,N-Myc,Max 2.4 0.28 0.13 0.002
V$HNF3B_01 HNF-3beta 2.3 0.17 0.08 0.008
V$SOX10_Q6 Sox2/4-6/9-12/18/20 2.3 0.20 0.09 0.005
V$ARNT_02 Arnt 2.3 0.27 0.12 0.005
V$ARP1_01 COUP-TFI/II (NR2F1/2) 2.2 0.37 0.17 0.0003
V$E47_02 MRF2,MASH-1,Myf5/6,MyoD,Myogenin, HTF4c,E47 2.1 0.28 0.13 0.002
V$NFAT_Q6 NFATC1-4 -4.8 0.02 0.11 0.002
V$AHRARNT_02 AhR,ARNT -3.1 0.03 0.11 0.009
V$TCF11MAFG_0 BACH1/2,MAF,MAFB/E/G/K,NFE2,NFE2L1-3 -3.1 0.03 0.11 0.009
V$OLF1_01 EBF1/3 -3.1 0.03 0.11 0.009
V$YY1_02 YY1 -2.7 0.7 0.16 0.005
V$XFD3_01 EP300,MEIS1,RRN3, SMAD2,TGIF1 -2.7 0.06 0.15 0.005
V$STAT3STAT3_Q3 STAT3 -2.7 0.07 0.19 0.002
V$FAC1_01 BPTF -2.6 0.07 0.17 0.003
V$CMYB_01 MYB,MYBL2 -2.4 0.06 0.15 0.009
V$FREAC3_01 FOXC1/D1/D3/F1/F2/H1/I1/J1/J2FOXL1/O1/O3/O4 -2.4 0.07 0.17 0.007
V$PAX8_01 PAX8 -2.4 0.07 0.16 0.007
V$ATF1_Q6 ATF1-4,ATF7,CREB1, CREM -2.1 0.1 0.21 0.007
V$HELIOSA_02 IKZF1 -2.1 0.12 0.24 0.006
Matrix name TFBS matrix from TRANSFAC database, Transcription factor TFs that can bind to the matrix element, Up/down factor over-
representation of the TFBS in upregulated versus downregulated genes (? sign) or in downregulated versus upregulated genes (- sign)
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123hypertrophy [56], and TFBS analysis showed that binding
sites for AhR were overrepresented in downregulated genes
after MI. Hannenhalli et al. [20] recently identiﬁed TFBS
overrepresented in differentially expressed genes in human
end-stage systolic heart failure. In that study, an important
role for the family of FOX transcription factors was found,
a number of which were also identiﬁed in our data set (see
Table 2). Except for the FOX family of TFs, their dataset
[20] shows remarkable little overlap with ours, which
might be explained by the distinction between early LV
hypertrophy versus end-stage heart failure, as well as the
older age of the human patients compared with the swine
used in this study and the usage of medication in the human
patient population.
Protein/DNA array analysis simultaneously assays the
DNA-binding activity of a large set of TFs and has pre-
viously been applied to cultured cardiomyocytes [8, 60],
but not to studies on TF activity in LV remodeling. Of the
TFs identiﬁed in the protein/DNA array that were not
conﬁrmed by the TFBS analysis, RAR has been implicated
in hypertrophy, although its role is controversial.The RAR
was found to suppress the a-adrenergic receptor-dependent
hypertrophy in isolated cardiomyocytes [68], whereas
overexpression of RAR in the heart caused dilated car-
diomyopathy in mice [4]. Furthermore, a recent report
suggests that retinoic acid induces a cardiac phenotype that
is more compatible with physiological hypertrophy [13].
Overrepresentation of the TFBS for the NFATc1-4
family in downregulated genes was unexpected, as NFATs
are considered transcriptional activators and NFATc1-4 are
activated in cardiac hypertrophy, at least in rodents [36].
Indeed, NFAT transcriptional activity was reported to be
increased in mice 3 weeks after MI [22]. This discrepancy
might be explained by NFAT5 binding to the TFBS of
NFATc1-4. In contrast to NFATc1-4, NFAT5 does not
have its own entry in the TRANSFAC database and would
therefore not be identiﬁed in the TFBS analysis. NFAT5
binds to the 50-TGGAAA(C/A/T)A(T/A)-30 motif, which
contains the NFATc1-4 cognate element 50-(T/A/
C)GGAA(A/G)-30 [37]. In line with this notion, using
protein/DNA array, we found NFAT5 DNA-binding
Table 3 Top 5 transcription factors showing increased or decreased
DNA-binding activity in nuclear extracts from MI myocardium
Probe name Transcription factor Ratio MI/sham
LyF IKZF1 ?
a
AIC/CBF COUP-TFI/II (NR2F1/2) 9.8
AF-1 COUP-TFII (NR2F2) 4.6
PEPCK PR GR (NR3C1) 2.5
ACP BP HIVEP1
c 2.5
RAR(DR5) RAR -?
b
ORE NFAT5 -9.9
HNF-3 FOXA1/2/3 -7.4
NF-Y NF-Y -6.7
MEF-1 MyoD
d -6.5
a Signal was only detectable on post-MI array
b Signal was only detectable on sham array
c HIVEP1 is the most likely candidate to bind to the ACPBP binding
element [1]
d MyoD is the most likely candidate to bind to the MEF-1 element
[39]
Fig. 3 Linking of TFs identiﬁed by protein/DNA array to differen-
tially expressed genes. TFs that show less (green outline) or more (red
outline) DNA-binding activity in post-MI LV tissue are depicted at
the far left and right and are connected with upregulated (red) and
downregulated (green) genes depicted in the center. TFs in yellow
show matching changes in both protein/DNA array and TFBS
analysis. A line was drawn between a TF and a gene if it was known
from the literature that the TF can cause the expression of the gene.
Uninterrupted and dashed lines indicate physical and indirect
interactions between molecules
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123activity to be reduced in MI hearts. Similarly, NFAT5
DNA-binding activity is decreased in pacing-induced heart
failure in dogs [53]. In contrast to NFATc1-4, NFAT5 is
not activated by calcineurin-mediated dephosphorylation
[37]. NFAT5 could play a role in cardiomyocyte survival,
as expression of a dominant negative protein in neonatal
cardiomyocytes decreased cell viability [24]. Interestingly,
no known NFAT5 target genes were identiﬁed among the
differentially expressed genes in our microarray analysis.
Further studies into the role of NFAT5 in cardiac remod-
eling are warranted.
For two TFs, matching data were found in TFBS and
protein/DNA array analysis, i.e., COUP-TFII and GR.
COUP-TFs are involved in suppression of genes involved
in fatty acid oxidation after pressure overload induced
hypertrophy [46]. We found COUP-TFII DNA-binding
activity to be increased in post-MI hearts and COUP-TFII
binding sites to be overrepresented in promoter regions of
upregulated genes. As COUP-TFs are mainly considered as
repressors of gene expression [44], our data could be
interpreted to suggest that the increase in COUP-TF
binding activity in post-MI hearts represents a compensa-
tory reaction, possibly as a response to the elevated
expression of target genes. Unfortunately no inhibitors of
COUP-TF are, to our knowledge, available, so its contri-
bution to LV remodeling could not be validated pharma-
cologically in vivo. The second TF identiﬁed by our
integrative approach was GR, which was extensively
linked to the microarray data (Fig. 3). We found that the
increase in cardiac mass was blunted by GR blockade with
mifepristone. These ﬁndings indicate that glucocorticoids
via the GR contribute to post-infarct hypertrophy of the
remote myocardium.
Glucocorticoids have been prescribed as anti-inﬂam-
matory agents and a large body of data has accrued on its
adverse effects on the heart. It was ﬁrst recognized that the
GR agonist dexamethasone, given as treatment for chronic
lung disease in pre-term children, can result in cardiac
hypertrophy [62]. In a large population-based study it was
shown that patients using glucocorticoids were at increased
risk of developing cardiovascular disease and a dose-
dependent increase in risk for development of heart failure
was observed [61]. Hyperproduction of cortisol in Cush-
ing’s syndrome is associated with cardiac hypertrophy,
which is reversed upon correction of hypercortisolism [43].
A role for local cardiac glucocorticoid production in
mediating LV hypertrophy in response to hemodynamic
overload was recently suggested by Ohtani et al. [42], who
reported that GR expression was upregulated in pressure-
overload hypertrophied LV of rats. Furthermore, cardio-
speciﬁc elevation of glucocorticoid production augmented
the hypertrophy response to pressure overload in mice [42].
Taken together these studies indicate that pharmacologi-
cally [61, 62], pathologically [43], or genetically [42]
induced hypercortisolism is able to produce or augment
hypertrophy. However, these studies do not answer the
Fig. 4 Effect of GR antagonist
mifepristone on cardiac
remodeling and function
following MI. Sham (n = 20),
MI (n = 24) and
MI ? mifepristone (n = 7)
animals were studied. a LVW/
BW ratios. b LV-dilation as
indicated by LV end-diastolic
area. c LV 2D-Ejection fraction.
d LV dP/dtP40.* P\0.05,
P\0.01,
P\0.001 vs.
sham,
§P\0.05 vs. MI.
Measurements are
mean ± SEM
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123question whether glucocorticoid signaling contributes to
LV hypertrophy under conditions of eucortisolism.
In mice with a recent MI, blocking GR with mifepri-
stone was recently shown to signiﬁcantly increase angio-
genesis [50]. This increased angiogenesis was associated
with improved infarct healing and a thicker scar area,
which likely contributed to the improved 2D ejection
fraction at 1–4 weeks after MI [34]. Unfortunately, the
authors did not report on LV end-diastolic dimensions or
LV weights. In contrast, we show here that GR contributes
to post-MI LV hypertrophy, as mifepristone attenuated LV
hypertrophy in MI pigs, while post-infarct LV dilatation
and 2D ejection fraction as well as LV systolic and dia-
stolic dysfunction were not affected. Thus, treatment with
mifepristone speciﬁcally blunted the post-MI increase in
LV mass, but failed to reverse the LV dilation and dys-
function. Although this observation is not readily
explained, it could be speculated that GR blockade may
have led to a pro-inﬂammatory state with a NF-jB medi-
ated increase in activity of metalloproteinases (MMPs) in
the remote area of the LV. Increased activity of MMPs has
been implicated in post-MI LV remodeling [52] and the
pro-hypertrophic calcineurin/NFAT pathway leads to
upregulation of MMPs [47]. Whether this mechanism was
indeed operative should be the subject of future studies.
Mifepristone was used to validate our transcriptional
genomics approach. Besides a GR antagonist, mifepristone
also acts as a progesterone receptor antagonist [2]. In our
study mifepristone was used to treat young prepubescent
animals of either sex. As plasma levels of progesterone are
very low before puberty [12], blocking of the progesterone
receptor will have had little contribution to the attenuated
hypertrophic response. Although mifepristone decreased
LV hypertrophy there was a trend towards decreased
ejection fraction and dP/dtP40. Hence, based on our data
therapeutic application of GR inhibition in post-infarct
patients would appear premature.
Pigs have a clear advantage over rodent models in
resembling humans more closely in terms of heart rates and
cardiac contractility [26], and autonomic control thereof
[10, 21], as well as myoﬁlament protein composition
[10, 21] and function [18], and calcium homeostasis [17].
Notwithstanding its translational power, an inherent
drawback of the pig as a model organism is that its genome
has not been fully sequenced yet. This leads to methodo-
logical challenges such as poor microarray annotation and
inability to perform TFBS analysis. With the ANEXdb the
annotation of the porcine microarray has been vastly
improved [6]. The output is the human homolog of the
porcine gene, which can then be used for TFBS analysis or
network analysis. The fact that human instead of porcine
genes had to be used for the TFBS analysis made experi-
mental validation of the results even more important. The
protein/DNA array directly measures the DNA-binding
activity of TFs, but an inherent limitation of the protein/
DNA array is that only a selection of TFs is analyzed. A
drawback of the TFBS analysis is that it cannot distinguish
between TFs that bind to similar motifs, which leads to
uncertainty as to which TF actually binds to the TFBS. By
combining the two data sets, we circumvented these limi-
tations and improved the reliability of the identiﬁcation of
TFs. Overcoming these experimental challenges is rewar-
ded by gaining insight into cardiac remodeling in a large
animal model with even better translational potential than
murine models.
In conclusion, we showed that an unbiased ‘-omics’
approach is feasible in a large laboratory animal. Using this
approach in which we combined microarray with in silico
TFBSanalysisandprotein/DNAarrayanalysistostudypost-
MI LV remodeling, we identiﬁed COUP-TFII and GR as
potential key mediators in post-MI remodeling. Subsequent
blockade of GR in vivo, demonstrated, for the ﬁrst time, that
GR contributes to the increase in LV mass after MI.
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